

AUSPICIES

Azienda Ospedaliero Universitaria delle Marche
AIL - *Associazione Italiana contro Leucemie-Linfomi e Mieloma*

Università Politecnica delle Marche

MEETING VENUE

Ego Hotel

Via Flaminia, 220 - 60126 Ancona
Tel.: +39 071 2181262

ITALIAN CME CREDITS

An application for Italian CME credits has been made as follows:

- Provider Studio ER Congressi SRL: ID 828-415098
- No. 4 CME credits for Physicians (disciplines: hematology, respiratory diseases, infectious diseases, interna medicine, oncology, paediatrics, pathological anatomy, clinical pathology, paediatrics), Biologist, Nurse, Paediatric nurse and Medical technician biomedical laboratory
- Educational objective: "guidelines-protocols-procedures"

OFFICIAL LANGUAGE

English

REGISTRATION

Registration is free and it is available at www.ercongressi.it - section "I nostri congressi/ anno 2024"

SCIENTIFIC SECRETARIAT

Prof. Attilio Olivieri

Clinica di Ematologia
Università Politecnica delle Marche
Azienda Ospedaliero Universitaria delle Marche

ORGANIZING SECRETARIAT

Studio ER Congressi Srl

Via de' Poeti, 1/7 - 40124 Bologna
Tel.: +39 051 4210559
E-mail: ercongressi@ercongressi.it
www.ercongressi.it

With an unrestricted educational grant of



SOLVE
ON.

neovii

sanofi

Mallinckrodt
Pharmaceuticals

Therakos
ECP Immunomodulation



program

GITMO Symposium

HOT TOPICS IN CHRONIC GVHD



OCTOBER 20-21, 2024

ANCONA, Ego Hotel

Sunday **October 20, 2024**

14:30 Open registration & welcome coffee

15:00-15:20 Welcome & introduction
A. Olivieri (Ancona)

15:20-18:00 **cGVHD part I**
Chairmen: F. Ciceri (Milano), M. Martino (Reggio Calabria)

15:20 cGVHD prophylaxis: are new strategies better than conventional tools? Yes
A. Nagler (Tela Aviv, IL)

15:40 cGVHD prophylaxis: are new strategies better than conventional tools? No
F. Bonifazi (Bologna)

16:00 ECP in the era of new drugs for cGVHD: which role and which schedule?
H. Greinix (Graz, AT)

16:20 Non immune effector targets in cGVHD
A. Olivieri (Ancona)

16:40 Ruxolitinib-refractory GVHD: it is still a worth definition?
M. Mohty (Paris, FR)

17:00 What to do in ruxolitinib-refractory cGVHD?
D. Wolf (Regensburg, DE)

17:20 Overlap cGVHD: assessment in the real life and proposal of a prospective GITMO study
D. Pulanic (Zagreb, HR), J. Mariotti (Milano)

17:40 Discussion

18:00 Closing part I

Monday **October 21, 2024**

08:45-09:45 **cGVHD part II: burning topics in lung cGVHD**
Chairmen: A. Bacigalupo (Genova), G. Moroncini (Ancona)

08:45 Round table: common and atypical lung manifestations in cGVHD in idiopathic pulmonary fibrosis and in CLAD
D. Wolf (Regensburg, DE), M. Bonifazi (Ancona), F. Rea (Padova)

09:45 Closing part II, remarks and farewell coffee

